Our report on activities & financial performance
throughout the year.
View an enhanced version of information about our annual meeting & matters to be voted upon.
Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.
Your vote is IMPORTANT!
Please vote your proxy online now or by phone by dialing 866-243-5513.
June 10, 2026
10:00 AM PT
You must register in order to attend the meeting.
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.
The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s Disease (FSCD).
Palisade Bio is now advancing towards two Phase 2 clinical studies in UC and Crohn’s disease (CD).